Discontinued — last reported Q3 '22
Year-over-year, this metric declined by 100.0%, from $139.50M to $0.00. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -100.0% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $646.00M | $9.56B | $333.00M | $17.00M | $60.00M | $227.00M | $333.00M | $0.00 | $0.00 | $0.00 | $5.61B | $139.50M | $139.50M | $139.50M | $139.50M | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | >999% | -96.5% | -94.9% | +252.9% | +278.3% | +46.7% | -100.0% | — | — | — | -97.5% | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — |
| YoY Change | — | — | — | — | -90.7% | -97.6% | +0.0% | -100.0% | -100.0% | -100.0% | >999% | — | — | — | -97.5% | -100.0% | -100.0% | -100.0% | -100.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.